Merrimack Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Merrimack Pharmaceuticals Inc.
CREF Stock Account
477,898
3.58%
0
0%
03/31/2018
Vanguard Total Stock Market Index Fund
303,329
2.27%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
184,813
1.39%
2
0%
07/31/2018
Franklin Biotechnology Discovery Fund
140,218
1.05%
0
0.06%
03/31/2018
DFA US Targeted Value Portfolio
98,990
0.74%
58,877
0.01%
04/30/2018
DFA US Small Cap Portfolio
85,584
0.64%
28,834
0%
04/30/2018
Federated MDT Small Cap Core Fund
79,151
0.59%
-23,534
0.06%
06/29/2018
Russell US Small Cap Equity Fund
68,491
0.51%
-9,786
0.02%
04/30/2018
CREF Global Equities Account
61,925
0.46%
0
0%
03/31/2018
Fidelity Spartan Extended Market Index Fund
58,611
0.44%
0
0%
07/31/2018
| Address |
One Broadway
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.merrimackpharma.com |
| Updated |
07/08/2019 |
| Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. |
